# Outset Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Outset Medical, Inc.). ## Overview Outset Medical, Inc. designs and commercializes the Tablo hemodialysis system, a dialysis platform used in acute care, post-acute care, and home settings. The company is based in the United States and sells a combination of capital equipment, consumables, service agreements, and related support services. ## Products & services • Tablo hemodialysis console and accessories • Tablo cartridges and other consumables • Service agreements, maintenance, and training • Cloud connectivity, software updates, and TabloHub support • Console operating leases in limited cases - **Hemodialysis consoles** (45%) — Tablo dialysis machines and related accessories sold to providers and care settings. - **Consumables** (35%) — Recurring cartridge and other disposable supplies used with Tablo systems. - **Service agreements** (15%) — Maintenance, repair, training, and software-enabled support contracts. - **Leases and other revenue** (5%) — Operating lease revenue and shipping/handling or other ancillary items. - Tablo hemodialysis console and accessories - Tablo cartridges and other consumables - Service agreements, maintenance, and training - Cloud connectivity, software updates, and TabloHub support - Console operating leases in limited cases ## Customers Outset Medical sells primarily to hospitals, health systems, and dialysis providers that use Tablo for acute and post-acute dialysis care. It also serves home hemodialysis patients through provider and clinic channels, with the provider typically making the purchasing decision and supporting patient training and deployment. - **Acute care hospitals and health systems** (primary) — Buy Tablo consoles, consumables, and support to run inpatient dialysis programs and insource services. - **Dialysis providers** (primary) — Use Tablo to expand fleet utilization, support outpatient and acute workflows, and manage dialysis delivery. - **Home hemodialysis programs** (secondary) — Adopt Tablo for home therapy because of ease of use, training simplicity, and patient support needs. - **Post-acute facilities** (secondary) — Skilled nursing facilities and LTACHs buy Tablo to support dialysis access in lower-acuity settings. - Hospitals and health systems buying Tablo for inpatient dialysis - Dialysis providers insourcing dialysis services with Tablo - Skilled nursing and long-term acute care facilities - Home hemodialysis programs and their provider partners - Customers buy for clinical flexibility, workflow, and cost control ## Geography The business is centered in the United States, where product and service revenue is generated primarily through direct sales. The company also notes competition and dialysis market activity in Europe and Asia, but its commercial footprint and customer coverage are mainly U.S.-based. - **United States** (100%) — Revenue is described as generated primarily through direct sales in the U.S. - United States is the primary revenue and sales market - Direct sales organization covers most major U.S. metropolitan markets - Manufacturing operations are partly outside the United States - Competition includes U.S., European, and Asian dialysis companies - Home and acute adoption depend on local provider networks ## Strategy Outset Medical’s strategy is to expand Tablo adoption in acute care, post-acute care, and home hemodialysis by proving clinical, operational, and economic benefits versus traditional dialysis delivery. It also aims to deepen utilization at existing customers through fleet expansion, service infrastructure, and training while broadening the installed base through direct sales. - **Expand Tablo penetration across care settings** (medium-term) — Broader adoption increases installed base, consumables pull-through, and recurring service revenue. - **Increase utilization and fleet expansion at existing customers** (short-term) — Higher utilization improves revenue per installed system and deepens customer relationships. - **Strengthen commercial and service infrastructure** (medium-term) — Dialysis equipment adoption depends on training, field service, and reliable support. - Expand Tablo adoption in acute, post-acute, and home settings - Sell on total cost of care, workflow, and clinical versatility - Grow installed base and increase utilization at existing accounts - Use one sales and service team across acute and home markets - Build evidence, training, and support to improve customer adoption ## Risks Outset Medical is exposed to concentration risk because revenue is tied to a single main product platform and a limited number of customers. The business also faces manufacturing, supply chain, and tariff risk because a significant portion of operations is outside the United States, while customer budget pressure and staffing shortages can slow purchasing and installation cycles. - **Customer concentration** [high] — A limited number of customers can cause volatile revenue if orders shift or contracts are lost. - **Single-product dependence** [high] — The business is heavily reliant on Tablo, so adoption or performance issues would affect revenue broadly. - **Manufacturing and supply chain disruption** [high] — International operations and third-party suppliers can be affected by labor, logistics, or trade issues. - **Customer budget and staffing pressure** [medium] — Hospitals and providers may delay capital spending and installations when labor or budgets are tight. - **Competitive pressure** [medium] — Larger dialysis companies have greater resources and installed relationships, which can slow market share gains. - Revenue concentration in Tablo and a small customer base - Customer budget pressure can delay capital purchases and installations - International manufacturing creates tariff and disruption risk - Single-source suppliers and contract manufacturing add supply risk - Competition from larger dialysis companies can pressure adoption ## Accounting Revenue recognition is important because Tablo sales include a mix of upfront console revenue, consumables recognized on shipment, and service agreements recognized over time. Investors should also watch inventory, warranty, and excess-obsolete provisions, plus lease accounting for console operating leases and any impairment or fair value judgments tied to financing and restructuring-related items. - **Revenue recognition mix** — Affects quarterly comparability and the mix between product and recurring revenue - **Inventory valuation and excess/obsolete reserves** — Can materially affect cost of product revenue - **Warranty accruals** — Affects gross margin and operating expense timing - **Lease accounting** — Can shift revenue recognition over the lease term - Console revenue is recognized when control transfers, usually on shipment - Service agreements are recognized ratably over the contract term - Consumables are recognized primarily upon shipment - Warranty and excess inventory reserves affect product cost - Operating leases and financing items can affect timing of revenue and expense --- *Last updated: 2026-04-29T04:44:44.628476+00:00*